Original Article Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and Once Daily Over 72 H Following Drug Cessation

Total Page:16

File Type:pdf, Size:1020Kb

Original Article Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and Once Daily Over 72 H Following Drug Cessation Antiviral Therapy 13:901–907 Original article Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation Marta Boffito1*, Laura Else 2, David Back2, Jessica Taylor1, Saye Khoo2, Marta Sousa1, Anton Pozniak1, Brian Gazzard1 and Graeme Moyle1 1St Stephen’s Centre, Chelsea and Westminster Hospital, London, UK 2Department of Pharmacology, University of Liverpool, Liverpool, UK *Corresponding author: E-mail: [email protected] Background: We investigated the pharmacokinetics of half-life over the respective dosing intervals (7.15 and atazanavir/ritonavir once daily and lopinavir/ritonavir twice 4.88 h for 0 –12 and 0–24 h, respectively). No partici- and once daily over 72 h following drug intake cessation. pant on atazanavir had concentrations below the min- Methods: This was an open-label, three-session, imum effective concentration (MEC) of 150 ng/ml at pharmacokinetic trial. Healthy volunteers received ata- 24 h. In total, 44% of the participants on lopinavir once zanavir/ritonavir 300/100 mg once daily and lopinavir/ daily had concentrations below the MEC of 1,000 ng/ml ritonavir 400/100 mg twice daily and 800/200 mg once at 24 h. At 16 h and 20 h, 13% and 63% of participants daily separately for 10 days. Pharmacokinetic profiles were below target for twice daily lopinavir, respectively. were assessed for each phase on day 10 over 72 h. At 36 h, all participants on lopinavir and 31% on ata- Pharmacokinetic parameters were determined over 12 zanavir were below target. Ritonavir area under the or 24 h and to the last measurable concentration by plasma concentration–time curve was 30% lower and non-compartmental methods. 26% higher when dosed at 100 mg or 200 mg with Results: Sixteen participants completed the study. lopinavir versus atazanavir. Geometric mean terminal elimination half-life to 72 h Conclusions: This study investigated the pharmacokinetic of atazanavir was 8.35 h and not different from the forgiveness of two boosted protease inhibitors. Whereas 0–24 h half-life (9.91 h). Terminal elimination half- the decline in lopinavir concentrations occured rapidly as life of lopinavir was 2.33 h (twice daily) and 2.44 h the boosting effect of ritonavir diminished, the rate of (once daily). These values were lower compared with the decline of atazanavir remained constant to 72 h. Introduction Combination antiretroviral therapy has transformed the patients [1]. Importantly, most protease inhibitors management of HIV infection and dramatically reduced must be coadministered with low dose ritonavir (100 HIV-related morbidity and mortality [1]. Despite these or 200 mg daily) in order to enhance patient exposure benefits, taking antiretroviral therapy can be challeng- to the full-dose protease inhibitor, thus preventing or ing. Many of the combination regimens are complex, overcoming resistance and allowing less frequent dos- have important adverse effects, can be difficult for ing. The advantages offered by ritonavir boosting are patients to adhere to and could lead to antiretroviral primarily attributable to its pharmacokinetic proper- drug resistance [1]. These concerns continue to limit ties. Ritonavir reduces the metabolism of concomitantly the success of antiretroviral therapy and complicate the administered protease inhibitors and changes their management of HIV-infected patients. pharmacokinetic parameters by inhibiting cytochrome The combination of a protease inhibitor and two P450 (mainly the isoform 3A4 [CYP3A4]) [2]. nucleoside or nucleotide reverse transcriptase inhibitors Boosted protease inhibitors differ in terms of dosing (N[t]RTIs) has been shown to achieve durable viral sup- schedule. Some are approved for once daily use; oth- pression in most antiretroviral-naive and -experienced ers are not, but in clinical practice are administered © 2008 International Medical Press 1359-6535 901 Boffito.indd 901 20/10/08 13:49:01 M Boffito et al. once daily to antiretroviral-naive patients in order to especially when their plasma concentrations decline simplify the daily dosing schedule and reduce the likeli- rapidly because of short half-lives. Delaying drug dos- hood of missed doses [1]. ing and allowing drug concentrations to fall to subther- Atazanavir is a potent HIV protease inhibitor that apeutic levels might lead to poorer virological control shows efficacy in both antiretroviral-naive and experi- and the emergence of resistance. However, information enced patients [3,4]. Atazanavir is a substrate of CYP3A4 on how frequently doses must be delayed in order to and coadministration with ritonavir has been shown to facilitate the emergence of resistance is lacking. significantly increase plasma atazanavir concentrations Recently, a study by Cohen et al. [9] examined the [4]. It has good oral bioavailability and pharmaco- feasibility of intermittent antiretroviral combination ther- kinetic properties that allow once daily dosing, either apy taken 5 days a week, with two consecutive days off. with or without ritonavir [4]. In the United States, ata- The study found that doses might be missed in the case of zanavir has been approved for first-line use either with regimens containing long half-life drugs, such as the non- or without ritonavir boosting, whereas in Europe it is NRTI efavirenz. However, the strategy appeared much only licensed for use in treatment-experienced patients, riskier for patients on protease inhibitors. In fact, five of boosted by ritonavir [1]. the six individuals on lopinavir/ritonavir or saquinavir/ Coformulated lopinavir/ritonavir-based antiretroviral ritonavir had subtherapeutic drug concentrations at the therapy (Kaletra®, Abbott Laboratories, North Chicago, end of the second day off therapy, suggesting that despite IL, USA) has shown durable virological treatment efficacy the presence of the ritonavir-boosting effect, lopinavir in clinical trials in both treatment-naive and - experienced and saquinavir plasma concentrations decline rapidly. patients [5] and is generally well tolerated. In this study we assessed the pharmacokinetics of The rapid and extensive first-pass oxidative metabo- atazanavir/ritonavir once daily and lopinavir/ ritonavir lism of lopinavir in the liver is mediated primarily by twice and once daily over 72 h following drug intake CYP3A4/5 isoenzymes; ritonavir inhibits the activity cessation. of CYP3A4 in a concentration-dependent manner in human liver microsomes resulting in increased plasma Methods lopinavir concentrations [5]. Lopinavir/ritonavir has been approved for twice daily Participants and ethics use (400/100 mg) in Europe and for twice (400/100 mg) The study protocol was approved by the Riverside and once (800/200 mg) daily use in the United States. Research Ethics Committee (London, UK) and by the Different clinical trials have shown similar virologi- Medicines and Healthcare products Regulatory Agency cal responses when comparing twice with once daily (London, UK) and was conducted according to the administration (in combination with two N[t]RTIs) in Declaration of Helsinki. patients with baseline viral loads <100,000 copies/ml. Written informed consent was obtained from healthy However, when comparing outcomes between these male and female volunteers aged between 18 and 65 treatments for patients with plasma HIV RNA levels years. Before entering the study, the volunteers were >100,000 copies/ml, a significant difference favouring established as HIV-negative and in good health by twice daily dosing was observed [6,7]. medical history, physical examination, electrocardio- Interestingly, protease inhibitors that are boosted by gram and standard haematological and blood chem- ritonavir could themselves affect ritonavir pharmaco- istry tests. None of the volunteers were receiving any kinetics. An analysis of several crossover pharmaco- concomitant medication, including oral contraceptives kinetic trials and clinical datasets showed that ritonavir or natural products. concentrations were different in the presence of differ- ent full-dose protease inhibitors [8]. Whereas slightly Study design higher than expected concentrations have been observed This was an open-label, three-session, pharmacokinetic following the administration of 100 mg of ritonavir trial carried out at the Pharmacokinetic Unit of the with atazanavir, significantly lower concentrations have St Stephen’s Centre, Chelsea and Westminster Hospital, been observed in the presence of lopinavir, fosampre- London, UK. navir and tipranavir [8]. This might be explained by During session one, volunteers were administered the different effects that the protease inhibitors have on atazanavir/ritonavir 300/100 mg once daily in the CYP3A4 activity, as this isoenzyme is also responsible morning for 10 days. On study days 10–13, atazanavir for ritonavir metabolism itself. and ritonavir plasma concentrations were assessed pre- Adherence to antiretroviral therapy is key for suc- dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, cessful treatment of HIV-infected persons [1]. Theoreti- 48, 60 and 72 h after dose administration. cally, antiretroviral agents should also be taken follow- After a washout period of 7 days, all participants were ing any restrictions on food and at the right time of day, administered lopinavir/ritonavir 400/100 mg twice daily 902 © 2008 International Medical Press Boffito.indd 902 20/10/08 13:49:01 Protease inhibitor concentration persistence for 10 days, with the omission of the evening lopinavir/
Recommended publications
  • Download Article PDF/Slides
    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
    [Show full text]
  • 1. Global HIV Infection Drug Market Overview 1.1 Global HIV Incidence Scenario 1.2 Market Overview: Global & Regional 1.3 Clinical Pipeline Overview
    August’2014 Global HIV Infection Drug Market & Pipeline Insight Global HIV Infection Drug Market & Pipeline Insight ©KuicK Research Global HIV Infection Drug Market & Pipeline Insight ©KuicK Research All rights reserved. No part of this research study may be reproduced, used, quoted and modified in any form and means without the prior consent of KuicK Research. The use of this research study is only allowed as per the license agreement/purchased from KuicK Research. Global HIV Infection Drug Market & Pipeline Insight ©KuicK Research Page 2 Table of Contents 1. Global HIV Infection Drug Market Overview 1.1 Global HIV Incidence Scenario 1.2 Market Overview: Global & Regional 1.3 Clinical Pipeline Overview 2. Global HIV Infection Drug Market Dynamics 2.1 Favorable Market Drivers 2.2 Market Challenges to be Resolved 2.3 Future Opportunity Outlook 3. FDA Regulatory Framework for Development of HIV Vaccine 3.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations 3.2 Guidance for Submitting HIV Resistance Data 3.3 HIV Resistance Testing in Antiretroviral Drug Development 3.4 HIV-1 Infection: Developing Antiretroviral Drugs for Treatment 4. EMA Regulatory Framework for Development of Medicinal Products for Treatment of HIV Infection 5. Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country 5.1 Phase Unknown 5.2 Research 5.3 Preclinical 5.4 Clinical 5.5 Phase-0 5.6 Phase-I 5.7 Phase-I/II 5.8 Phase-II 5.9 Phase-III 5.10 Preregistration 5.11 Registered Global HIV Infection Drug Market & Pipeline Insight ©KuicK Research Page 3 6.
    [Show full text]
  • Bictegravir 50Mg/Emtricitabine 200Mg/Tenofovir Alafenamide 25Mg (Biktarvy®) with Other Antiretrovirals
    FINAL VERSION – 2020-MAR -26 Title: Bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (Biktarvy®) with other antiretrovirals Issue Statement Bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (Biktarvy®) is approved by Health Canada for use as a complete regimen for the treatment of HIV-1 infection in adults with no known resistance to the components of the product [Biktarvy® Product Monograph {PM}]. Coadministration of Biktarvy® in combination with other antiretroviral agents is therefore off-label. However, we recogniZe that such use may be considered under specific circumstances, e.g. in patients with multidrug-resistant HIV-1 who require a multi-class antiretroviral regimen to achieve or maintain virologic suppression. The BC-CfE has received a number of requests for Biktarvy® in combination with other antiretrovirals; therefore, we require a consistent, evidence-based approach to handle such prescriptions. Background Biktarvy® is a three-drug fixed-dose combination containing bictegravir 50mg, emtricitabine 200mg, and tenofovir alafenamide 25mg [Biktarvy® PM]. Because Biktarvy® was developed as a complete single-tablet regimen, little information is available regarding its use with concomitant antiretrovirals. The potential safety and efficacy of such regimens could be impacted by drug-drug interactions between the component drugs of Biktarvy® and the concomitant antiretrovirals. The pharmacokinetic properties of tenofovir alafenamide (TAF) and bictegravir are reviewed below. Emtricitabine (FTC) is not expected to contribute significantly to drug-drug interactions with protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) [University Health Network {UHN}/Toronto General Hospital {TGH}; Liverpool HIV Drug Interactions website {Liverpool}]. Two fixed-dose combinations of FTC and TAF are available and approved by Health Canada [Descovy® PM]: o FTC/TAF 200/25 mg is recommended when used in combination with NNRTIs, unboosted integrase inhibitors, or unboosted ataZanavir.
    [Show full text]
  • Is There a True Difference in Efficacy and Safety?
    Journal of Virus Eradication 2018; 4: 73–80 ORIGINAL RESEARCH Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? Andrew Hill1*, Sophie L Hughes2, Dzintars Gotham2 and Anton L Pozniak3 1 Department of Pharmacology and Therapeutics, University of Liverpool, UK 2 Faculty of Medicine, Imperial College London, UK 3 Chelsea and Westminster Hospital NHS Foundation Trust, London, UK Abstract Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by 25–37%. When combined with RTV or COBI, the dose of tenofovir alafenamide (TAF) is lowered from 25 mg to 10 mg daily, but the TDF dose is maintained at 300 mg daily. Objective: To assess the differences in safety and efficacy between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in regimens with and without the pharmacokinetic boosters RTV and COBI. Methods: A PubMed/Embase search inclusive of dates up to 17 July 2017 identified 11 randomised head-to-head trials (8111 patients) of TDF versus TAF. The Mantel–Haenszel method was used to calculate pooled risk differences and 95% confidence intervals using random-effects models. A pre-defined sub-group analysis compared TAF with TDF, either when boosted with RTV or COBI, or when unboosted. Results: Nine clinical trials compared TAF and TDF for treatment of HIV-1 and two were for hepatitis B treatment. The eleven clinical trials documented 4574 patients with boosting RTV or COBI in both arms, covering 7198 patient-years of follow-up.
    [Show full text]
  • Current Status of New Antiretroviral Drugs in Development
    International AIDS Society–USA Topics in HIV Medicine Perspective Current Status of New Antiretroviral Drugs in Development At the International AIDS Society–USA HIV Nucleoside Reverse (Margolis et al, J Acquir Immune Defic course in Washington, DC, in May Transcriptase Inhibitors Syndr Hum Retrovirol, 1999; Ying et al, 2002, Roy M. Gulick, MD, MPH, dis- Antiviral Res, 2000). Phase 2 studies of cussed characteristics of select investi- Amdoxovir amdoxovir, both with and without gational antiretroviral drugs, including mycophenolic acid, are in progress. new reverse transcriptase and pro- Amdoxovir (DAPD) is an investigational tease inhibitors and drugs that inhibit HIV Nonnucleoside Reverse HIV entry and integration. guanine analogue active in vitro against both HIV and hepatitis B virus. Transcriptase Inhibitors Pharmacokinetic data support twice- Currently, 16 antiretroviral drugs are daily dosing of the compound. BMS 56,1390 (DPC-083) approved for treatment of HIV infection. Amdoxovir is active in vitro against A number of NNRTIs that are structural- However, even the best currently avail- zidovudine-resistant and lamivudine- ly related to efavirenz have been devel- able regimens pose challenges with resistant virus and some multidrug- oped, and the leading clinical candidate regard to adherence, toxicity, antiviral resistant strains with the reverse tran- activity, and resistance. New drug devel- scriptase codon 69 insertion. The Table 1. New Formulations and opment thus confronts the need for reverse transcriptase mutations K65R improved convenience and tolerability, Dosing Strategies of Existing and L74V reduce susceptibility to the Antiretroviral Drugs reduced toxicity, and improved activity compound in vitro. The K103N mutation against both wild-type and drug-resis- associated with efavirenz resistance may tant viruses.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Full PDF of 2003 Pipeline Report
    Antiretrovirals Pipeline Report prepared for Treatment Action Group by Rob Camp Table of contents 1. New agents chart..............................................................................................................2 Extracellular agents ............................................................................................................3 NRTIs ................................................................................................................................. 11 NNRTIs .............................................................................................................................. 15 Transcriptase and Integrase inhibitors.......................................................................... 19 Protease inhibitors ........................................................................................................... 21 Budding/maturation inhibitors......................................................................................... 33 Antivirals Pipeline Report The pipeline is bursting, with at least the following compounds twinkling in the eyes of scientists around the globe. It is by no means a full list, but those substances in red were presented at the recent CROI in Boston. There seems to be no lack of investigation — bench scientists are having a field day! Compound Class of Compound Phase of Pharmaceutical Co. Development TAK 220 CCR5 antagonist Preclinical Takeda PRO 140 CCR5 antagonist Preclinical Progenics AK 602 CCR5 antagonist Preclinical Ono/Moravek SCH D CCR5 antagonist
    [Show full text]
  • REYATAZ Rx Only
    ® REYATAZ Rx only (atazanavir sulfate) Capsules (Patient Information Leaflet Included) DESCRIPTION REYATAZ® (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease. The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1- dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]- 2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester, sulfate (1:1). Its molecular formula is C38H52N6O7•H2SO4, which corresponds to a molecular weight of 802.9 (sulfuric acid salt). The free base molecular weight is 704.9. Atazanavir sulfate has the following structural formula: Atazanavir sulfate is a white to pale yellow crystalline powder. It is slightly soluble in water (4-5 mg/mL, free base equivalent) with the pH of a saturated solution in water being about 1.9 at 24 ± 3° C. REYATAZ Capsules are available for oral administration in strengths containing the equivalent of 100 mg, 150 mg, or 200 mg of atazanavir as atazanavir sulfate and the following inactive ingredients: crospovidone, lactose monohydrate, and magnesium stearate. The capsule shells contain the following inactive ingredients: gelatin, FD&C Blue #2, and titanium dioxide. The capsules are printed with ink containing shellac, titanium dioxide, FD&C Blue #2, isopropyl alcohol, ammonium hydroxide, propylene glycol, n-butyl alcohol, simethicone, and dehydrated alcohol. 1 of 47 Approved v1.0 CLINICAL PHARMACOLOGY Microbiology Mechanism of Action Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.
    [Show full text]
  • Design, Synthesis, and Structure-Activity Relationship Investigation of 3’,4’-Disubstituted Pyranochromone Derivatives with Diverse Biological Activities
    DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIP INVESTIGATION OF 3’,4’-DISUBSTITUTED PYRANOCHROMONE DERIVATIVES WITH DIVERSE BIOLOGICAL ACTIVITIES Ting Zhou A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Eshelman School of Pharmacy. Chapel Hill 2010 Approved by Kuo-Hsiung Lee, PhD (Advisor) Kenneth F. Bastow, PhD Jian Liu, PhD Qian Shi, PhD Chin-Ho Chen, PhD i ©2010 Ting Zhou ALL RIGHTS RESERVED ii ABSTRACT TING ZHOU: DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIP INVESTIGATION OF 3’,4’-DISUBSTITUTED PYRANOCHROMONE DERIVATIVES WITH DIVERSE BIOLOGICAL ACTIVITIES (Under the direction of Kenan Professor Kuo-Hsiung Lee) The overall goals of this research are to design and synthesize novel 3’,4’- disubstituted pyranochromone derivatives, to evaluate their anti-HIV activity and chemosensitizing potency, to elucidate structure-activity relationships (SAR), and to discover novel chemical entities. 3’R,4’R-Di-camphanoyl-khellactone analogs (DCKs) was first identified in our laboratory with high anti-HIV activity against wild-type HIV strain early in 1994. Using SAR-directed strategy, 3’R,4’R-di-camphanoyl-pyranochromone analogs (DCPs) were synthesized and evaluated in a continuing study, which showed high potency against both wild-type and multi-RT inhibitor-resistant strains. Mechanism study of DCK and its derivatives suggested that the compounds target HIV-RT in a unique way, by inhibiting its DNA-dependent DNA polymerase activity. A microwave-assisted one-pot reaction was first developed in our study and successfully applied in the preparation of 2’,2’-dimethyl-chromone motifs which were iii key intermediates in DCK and DCP derivatives.
    [Show full text]
  • Tenofovir Alafenamide-Emtricitabine (Descovy)
    © National HIV Curriculum PDF created September 25, 2021, 1:23 am Tenofovir alafenamide-Emtricitabine (Descovy) Table of Contents Tenofovir alafenamide-Emtricitabine Descovy Summary Drug Summary Key Clinical Trials Resistance Key Drug Interactions Drug Summary Tenofovir alafenamide-emtricitabine is a 2 nucleoside reverse transcriptase inhibitor (NRTI) component of multiple approved first-line treatment options, including multiple single-tablet regimens. Tenofovir alafenamide is a prodrug of tenofovir that is hydrolyzed to tenofovir in plasma, and then phosphorylated to the active compound within cells. When compared with tenofovir DF, tenofovir alafenamide generates approximately 90% lower tenofovir plasma levels, which correlates with an improved safety profile. In addition, tenofovir alafenamide does not accumulate in renal tubular cells. Studies have shown that tenofovir alafenamide, when compared with tenofovir DF, causes less adverse impact on renal proximal tubule function and bone mineral density. At this time, data on the long-term clinical impact related to differences in these parameters are lacking. Tenofovir alafenamide-emtricitabine is FDA-approved for use in mild-moderate renal insufficiency (creatinine clearance as low as 30 mL/min). The tenofovir alafenamide component is FDA approved for the treatment of hepatitis B. At this time, data are lacking to support the use of tenofovir alafenamide for postexposure prophylaxis (PEP). Tenofovir alafenamide-emtricitabine recently received FDA approval for HIV preexposure prophylaxis (PrEP) for at-risk adults and adolescents who weight at least 35 kg to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. Tenofovir alafenamide-emtricitabine is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectiveness in this population has not been evaluated.
    [Show full text]
  • GRADE Table: Atazanavir/Ritonavir Vs. Lopinavir/Ritonavir 1
    GRADE Table: Atazanavir/ritonavir vs. Lopinavir/ritonavir Question: Should Atazanavir/ritonavir vs. Lopinavir/ritonavir be used for patients failing first line therapy? Settings: Bibliography: Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once daily atazanavir/ritonavir versus twice daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55. Molina JM, Andrade- Villanueva J, Echevarria J, et al. Atazanavir/ritonavir vs. Lopinavir/ritonavir in antiretroviral naïve HIV-1-infected patients: CASTLE 96 week Efficacy and Safety. 48th Annual ICAAC/IDSA Meeting, October 25-28, 2008, Washington DC. Abstract H-1250d. Summary of findings Quality assessment No of patients Effect Importance No of Other Relative Quality Design Limitations Inconsistency Indirectness Imprecision Atazanavir/ritonavir Lopinavir/ritonavir Absolute studies considerations (95% CI) Mortality (follow-up 48 weeks) 1 randomised no serious no serious serious serious3 none 0 more per RR 1.01 trials limitations1 inconsistency indirectness2 1000 (from 9 ⊕⊕ΟΟ 6/440 (1.4%) 6/443 (1.4%) (0.33 to CRITICAL fewer to 28 LOW 3.1) more) Severe adverse events (follow-up 96 weeks)4 1 randomised serious1 no serious serious serious3 none 29 more per RR 1.25 trials inconsistency indirectness2 1000 (from 14 63/441 (14.3%) 50/437 (11.4%) (0.88 to ⊕ΟΟΟ CRITICAL fewer to 88 VERY LOW 1.77) more) Clinical disease progression - not
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]